hACE2 receptor binding inhibition antibodies
In the ChAdOx1 nCoV-19 prime cohort at day 29, SII-NVX-CoV2373 booster induced 3.1 fold-rise (95% CI 2.2, 4.3), 3.3 fold-rise (95% CI 2.5, 4.5), and 3.3 fold-rise (95% CI 2.4, 4.5) in GMTs against Wuhan, Omicron BA.1 and Omicron BA.5, respectively, while ChAdOx1 nCoV-19 booster induced 2 fold-rise (95% CI 1.5, 2.6), 2 fold-rise (95% CI 1.4, 2.7), and 1.8 fold-rise (95% CI 1.2, 2.7) in GMTs, respectively. The seroresponse rate was 69% (95% CI 47.08, 86.79), 78.26% (95% CI 56.30, 92.54) and 78.26% (95% CI 56.30, 92.54) against Wuhan, Omicron BA.1 and Omicron BA.5, respectively with the SII-NVX-CoV2373 booster at day 29, while it was 39.13% (95% CI 19.71, 61.46), 43.48% (95% CI 23.19, 65.51) and 39.13% (95% CI 19.71, 61.46), respectively with the ChAdOx1 nCoV-19 booster. At day 181, there was 2 fold-rise (95% CI 1.0, 3.9), 3.7 fold-rise (95% CI 1.9, 7.1), and 3.4 fold-rise (95% CI 1.8, 6.3) in GMTs against Wuhan, Omicron BA.1 and Omicron BA.5, respectively, in the SII-NVX-CoV2373 group, while there was 1.4 fold-rise (95% CI 1.0, 2.0), 2.4 fold-rise (95% CI 1.5, 3.8), and 2 fold-rise (95% CI 1.3, 3.1) in GMTs, respectively, in the ChAdOx1 nCoV-19 group. At day 181, in the SII-NVX-CoV2373 group seroresponse rate was 45.45% (95% CI 24.39, 67.79), 63.64% (95% CI 40.66, 82.80) and 59.09% (95% CI 36.35, 79.29) against Wuhan, Omicron BA.1 and Omicron BA.5, respectively, while in the ChAdOx1 nCoV-19 group it was 26.09% (95% CI 10.23, 48.41), 52.17% (95% CI 30.59, 73.18) and 52.17% (95% CI 30.59, 73.18), respectively (Tables In BBV152 prime cohort, SII-NVX-CoV2373 booster induced 9.7 fold-rise (95% CI 5.9, 15.9), 7.1 fold-rise (95% CI 4.4, 11.4), and 7 fold-rise (95% CI 4.3, 11.3) in GMTs against Wuhan, Omicron BA.1 and Omicron BA.5, respectively, while there was no rise in GMTs against any of these strains with BBV152 booster. The seroresponse rate was 100% (95% CI 85.18, 100.00), 91.30% (95% CI 71.96, 98.93) and 86.96% (95% CI 66.41, 97.22) against Wuhan, Omicron BA.1 and Omicron BA.5, respectively in the SII-NVX-CoV2373 group, while it was 13.04% (95% CI 2.78, 33.59) and 4.35% (95% CI 0.11, 21.95) against Omicron BA.1 and Omicron BA.5, respectively in the BBV152 group with no seroresponse seen against Wuhan. At day 181, in the SII-NVX-CoV2373 group seroresponse rate was 72.73% (95% CI 49.78, 89.27), 77.27% (95% CI 54.63, 92.18) and 72.73% (95% CI 49.78, 89.27) against Wuhan, Omicron BA.1 and Omicron BA.5, respectively, while in the BBV152 group it was 34.78% (95% CI 16.38, 57.27), 73.91% (95% CI 51.59, 89.77) and 65.22% (95% CI 42.73, 83.62), respectively (Tables 